3,4-Diaminopyridine in the treatment of congenital (hereditary) myasthenia.

Congenital or hereditary myasthenia describes a heterogeneous group of disorders in which the immune system is not implicated. Treatment has previously depended on anticholinesterase medication. The effectiveness of 3,4-diaminopyridine (3,4-DAP), a preparation that enhances acetylcholine release fro...

Descrición completa

Detalles Bibliográficos
Main Authors: Palace, J, Wiles, C, Newsom-Davis, J
Formato: Journal article
Idioma:English
Publicado: 1991